ArticleEuropean journal of nuclear medicine and molecular imaging2026
Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01483027 (A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEPOCH demonstrated superior progression free survival using yttrium-90 [ PATIENTS AND
methodsLiver-related treatment-emergent adverse event (TEAE) frequency and/or severity, and bilirubin increase were explored in participating patients. For hypothesis generation, a theoretical model was constructed to understand EPOCH dosimetry in the absence of multicompartment dosimetry data.
resultsLiver-related TEAEs were reported in 93/186 (50%) patients, TEAEs ≥ grade 3 in 44/186 (24%) patients. A total of 26/186 patients (14%) experienced a bilirubin increase TEAE of any grade, in five of which assessed as related to glass [
conclusionWhen treatment is same-day whole liver at 120 Gy average absorbed dose, the normal liver absorbed dose is dependent on fractional tumour involvement.
trial registrationClinicalTrials.gov NCT01483027.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.